ERBB2 and breast cancer: In the Canadian REaCT-HER TIME study, patients with HER2-positive breast cancer who achieved a pCR will complete a total of 6 months of adjuvant trastuzumab, regardless of their initial clinical stage or the chemotherapy backbone received (NCT04928261) [48].